Open Forum Infect Dis . Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies

[tetano]

Open Forum Infect Dis


. 2022 Apr 14;9(7):ofac204.
doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies


Zachary A Yetmar ¹ , Ryan B Khodadadi ¹ , Maria Teresa Seville ² , Lisa Brumble ³ , John C O'Horo ¹ , Ravindra Ganesh ⁴ , Raymund R Razonable ¹



Affiliations

• PMID: 35791358
• PMCID: PMC9047222
• DOI: 10.1093/ofid/ofac204

Free PMC article

Abstract

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.

Keywords: COVID-19; SARS-CoV-2; anti-CD20; monoclonal antibody; rituximab.